Therapeutic Trial of Metformin and Bortezomib in a Mouse Model of Tuberous Sclerosis Complex (TSC)
Neil Auricchio(Brigham and Women's Hospital), David J. Kwiatkowski(Brigham and Women's Hospital)
Cited by 28
Related Papers
Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function
|Journal of Neuroscience|2008|502
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR
|Journal of Clinical Investigation|2003|479
A Mouse Model of Tuberous Sclerosis: Neuronal Loss of Tsc1 Causes Dysplastic and Ectopic Neurons, Reduced Myelination, Seizure Activity, and Limited Survival
|Journal of Neuroscience|2007|460
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
|Journal of Clinical Investigation|2007|381
Regulable neural progenitor-specific <i>Tsc1</i> loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex
|Proceedings of the National Academy of Sciences|2011|178